

CSE Symbol: IME
OTC PINK Symbol: IMEXF
Frankfurt & Stuttgart Symbol: DPD2

NR-2016-IME-10

Imagin Medical Attends American Urological Association Annual Meeting

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting bladder cancer through endoscopes.

Vancouver, B.C. and Boston, MA, May 24, 2016 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”), as previously reported, attended the [2016 American Urologic Association Annual Meeting](#), held in San Diego, CA, May 6-10, attended by over 16,000 urologic healthcare providers from around the world. More than 260 companies exhibited their products at the city’s main convention center.

Jim Hutchens, Imagin’s President and CEO and Thom McMahon, Imagin’s VP of Sales, attended the conference with three objectives in mind: conduct market research, meet with potential medical and pharmaceutical partners and establish relationships with additional key physicians to join Imagin’s Scientific Advisory Board.

After much interaction with attendees and exhibitors, it became apparent that there is a significant need for a more practical method to visualize and detect bladder cancer more rapidly and accurately. The vast majority of cancers are detected using a traditional cystoscope with white light, which is not very effective with cancers that grow beneath the bladder wall. New methods use chemical imaging agents with blue light that can better visualize bladder cancer. This procedure has been accepted into the AUA Guidelines. However, the imaging agents require an hour to be absorbed by the bladder, making the logistics of using these products in the operating room challenging. Our research and recent meetings with some of the world’s top physicians continue to support demand for the i/Blue Imaging system that can produce better images in less than 15 minutes.

Mr. Hutchens held successful meetings with medical device companies with large distribution channels, as well as pharmaceutical companies that are involved with fluorescent drugs.

Lastly, Mr. Hutchens and Dr. Ralph deVere White, the Director of the Comprehensive Cancer Center at UC Davis, a worldwide leader in bladder cancer, and the Chairman of Imagin's Scientific Advisory Board, met with many physicians from leading institutions in the United States who had significant interest in working with the Company. Over the course of the summer, Imagin plans to announce new members of its Scientific Advisory Board.

About Imagin Medical

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.

ON BEHALF OF THE BOARD:

Jim Hutchens,

President & CEO

For further information, contact:

Bill Galine, Investor Relations

Telephone: (775) 737-3292

Email: billgaline@gmail.com

CAUTIONARY DISCLAIMER STATEMENT: *The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.*

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.